Listed by the USPTO as WRIGHT, ERIC BRANDON
Tech Center 1600 • Art Units: 1632 1638 1651
This examiner grants 0% of resolved cases
WRIGHT, ERIC BRANDON is assigned to Tech Center 1600 and Art Unit 1632. The profile records 1 resolved case, a 0.0% allowance rate, a 0.0% interview lift, and a median of 1051 days to allowance. Because the record contains only one matter, the outcome and neutral interview measure provide very limited information about future prosecution. The median figure describes the recorded case but should not be treated as a stable expectation.
The listed companies are Regeneron Pharmaceuticals Inc., Al Chi Mi A S R L, and Industry-academic Cooperation Foundation, Yonsei University. The listed firms are Maschoff Brennan, FOLEY HOAG, LLP (General), and Jordan IP Law, LLC. Practitioners should rely on the application’s technical record and the specific office action rather than extrapolating from this profile. Interviews may support clarification, but no measurable effect is shown.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18467024 | SPLIT-INTEIN METHODS AND COMPOSITIONS FOR GENERATION OF SINGLE SEX OFFSPRING | Final Rejection | Individual inventor |
| 18478273 | CORRECTION OF HEPATOSTEATOSIS IN HUMANIZED LIVER ANIMALS THROUGH RESTORATION OF IL6/IL6R/GP130 SIGNALING IN HUMAN HEPATOCYTES | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18711180 | FEED COMPOSITION FOR CONSTRUCTION OF STEATOHEPATITIS ANIMAL MODEL | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 18696610 | METHOD FOR SEPARATING PITUITARY CELLS AND HYPOTHALAMIC CELLS USING CELL SURFACE MARKER | Non-Final OA | National University Corporation Tokai National Higher Education and Research System |
| 18513051 | CELL AND COLLAGEN COMPOSITIONS FOR ENGINEERED CARDIAC TISSUE | Non-Final OA | BROWN UNIVERSITY |
| 19106285 | METHOD AND SYSTEM FOR TREATMENT OF BONE OR JOINT | Non-Final OA | REDDRESS LTD. |
| 18706831 | EPIGENETIC TARGETS IN CLONAL HEMATOPOIESIS | Non-Final OA | Sloan-Kettering Institute for Cancer Research |
| 18876664 | METHOD FOR PRODUCING MATURE DENDRITIC CELLS | Non-Final OA | LIHPAO LIFE SCIENCE CORP. |
| 18605786 | GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 AND MOUSE TREM2 P.R47H AND METHODS OF USE THEREOF | Final Rejection | Indiana University Research and Technology Corporation |
| 18946035 | Methods for Improving Tissue Graft Storage Conditions through the Reduction of Senescence | Non-Final OA | Restoration Biologics LLC |
| 18899858 | IN VITRO EXPANSION METHOD FOR CULTIVATING MEMORY IMMUNE CELL | Non-Final OA | SHANGHAI NAICON BIOTECHNOLOGY CO., LTD. |
| 18093767 | PROTECTIVE SOLUTION FOR ISOLATING MITOCHONDRIA, USE THEREOF, KIT COMPRISING THE SAME, AND METHOD FOR ISOLATING MITOCHONDRIA | Final Rejection | TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO., LTD. |
| 18835557 | COMPOSITIONS | Non-Final OA | Imperial College Innovations Ltd |
| 18598152 | CARDIAC ORGANOID AND ANTI-ELECTRO-MITOCHONDRIAL DESYNCHRONIZATION THERAPY | Non-Final OA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. |
| 18722978 | ANTICOAGULANT MANGANESE-CONTAINING STEM CELL COATING, PREPARATION METHOD AND USE THEREOF | Non-Final OA | The Affiliated Stomatological Hospital of Chongquing Medical University |
| 18719347 | NUCLEIC ACID EXPRESSION PLATFORM WITH INCREASED EXPRESSION EFFICIENCY | Non-Final OA | SML BIOPHARM CO., LTD. |
| 18693293 | METHOD FOR PRODUCING HUMAN ARTIFICIAL CHROMOSOME VECTOR IN HUMAN CELL | Non-Final OA | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY |
| 18506219 | PRESERVATION SOLUTION, PRESERVATION SYSTEM AND METHOD FOR PRESERVING BIOLOGICAL TISSUES IN VITRO, IN PARTICULAR CORNEAL TISSUES | Final Rejection | AL.CHI.MI.A. S.R.L. |
| 18506225 | PRESERVATION SOLUTION, PRESERVATION SYSTEM AND METHOD FOR PRESERVING BIOLOGICAL TISSUES IN VITRO, IN PARTICULAR CORNEAL TISSUES | Final Rejection | AL.CHI.MI.A. S.R.L. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy0.0% of resolved applications examined by Eric Brandon Wright were allowed (1 resolved cases), compared with 38.1% across Art Unit 1632 over the last five years.
This examiner's interview lift is +0.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Eric Brandon Wright took 1,051 days on average from filing to allowance.
Eric Brandon Wright examines applications in Art Unit 1632 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
